Delix Therapeutics
PrivateLast Round
Series C
Aug 18, 2026
Est. Valuation
$275M
Total Funding Raised
$126.2M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Delix Therapeutics is a biotechnology company that develops novel, non-hallucinogenic psychoplastogen therapeutics to treat severe psychiatric and neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Delix Therapeutics Comparables
Compare Delix Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lophora | 86% | |
| Gilgamesh Pharmaceuticals | 85% | |
| Xylo Bio | 83% | |
Delix Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 18, 2026 | ||||
| Strategic | Sep 10, 2025 | ||||
| Grant | Jun 4, 2024 | ||||
| Grant | Dec 13, 2023 | ||||
| Convertible Debt | Jan 10, 2022 | ||||
Debt | Jan 10, 2022 |
Key People
Founding team and executive leadership
Delix Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Casa Verde Capital | Series A |
| National Institute on Drug Abuse | Grant |
| RA Capital Management | Series A |
| Dolby Family Ventures | Series A |
| United States Department of Defense | Grant |
| U.S. Department of Defense | Grant |
| NIH RADx | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 18, 2026
Raised $85M led by Johnson & Johnson
- Jun 4, 2024
$825K grant from U.S. Department of War and Department of Defense.
Delix Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Delix Therapeutics's valuation, stock price, and market status.